Tofacitinib (Xeljanz)

Pfizer

Description

Janus kinase inhibitor

Indications

Moderate-to-severely active UC in adults under 65 years

Contraindications

Do not use in absolute lymphocyte count <750 cells/mm3; absolute neutrophil count <1000 cells/mm3; haemoglobin less than 9g/dL; serious infection (active); tuberculosis (active). Avoid in pregnancy or while breastfeeding. Caution in patients over 65; moderate or severe renal impairment; malignancy; predisposition to infection; risk factors for venous thromboembolism; risk of viral reactivation, diverticulitis or gastrointestinal perforation. Patients should receive all recommended vaccinations and be evaluated for tuberculosis and viral hepatitis before treatment. | Potential side effects: Abdominal pain; anaemia; cough; diarrhoea; indigestion; fatigue; fever; gastrointestinal disorders; headache; high blood pressure; increased risk of infection; influenza; joint disorders; nausea; sore throat; sinus infection; skin reactions; vomiting

Preparations Available

Oral tablet (film-coated or modified release)

Quantity

Dose: 5mg twice daily (film–coated); 11mg once daily (modified–release)

Sizes Available

5mg tablets (56), £690.03; 10mg tablets (56), £1380.06; 11mg modified-release tablets (28), £690.03

Price

5mg tablets (56), £690.03; 10mg tablets (56), £1380.06; 11mg modified-release tablets (28), £690.03

More on: Janus kinase inhibitors